Main Uses of Oftan Chlora

Oftan Chlora is an ophthalmic antibiotic preparation containing chloramphenicol. It is primarily used for the local treatment of external eye infections caused by bacteria that are sensitive to this specific antibiotic.

The medication is commonly indicated for the following conditions:

• Bacterial Conjunctivitis: Inflammation of the conjunctiva, the thin membrane covering the white part of the eye and the inner surface of the eyelids, when caused by bacterial pathogens.
• Bacterial Keratitis: Infections of the cornea, the clear front surface of the eye.
• Blepharitis: Bacterial infection or inflammation of the eyelid margins.
• Dacryocystitis: Infection of the tear sac.

Benefits and Mechanism of Action

The primary benefit of Oftan Chlora is its broad-spectrum antimicrobial activity. Chloramphenicol works by penetrating the bacterial cell and inhibiting protein synthesis, which prevents the bacteria from growing and multiplying.

Key therapeutic advantages include:

• Broad Spectrum: Effectiveness against a wide variety of both Gram-positive and Gram-negative bacteria.
• Deep Tissue Penetration: The ability of the active substance to penetrate the ocular tissues effectively, reaching the site of infection.
• Symptom Relief: By addressing the underlying bacterial cause, the medication helps reduce common symptoms of infection such as redness, swelling, discharge, and irritation.

Oftan Chlora (Chloramphenicol Ophthalmic) eligibility is strictly defined by regulatory documents, particularly concerning risks of bone marrow toxicity and immature metabolism.

Contraindicated Populations (Must Not Use)

Classification	Population/Condition
Absolute Contraindication	Individuals with a personal or family history of aplastic anaemia or other blood dyscrasias [2.6].
Absolute Contraindication	Patients with a history of myelosuppression from previous chloramphenicol exposure or known hypersensitivity to the active substance or excipients [2.6].
Absolute Contraindication	Patients with acute porphyria [1.7].

Restricted and Conditional Use

Classification	Restriction Details
Age-Related	Neonates less than one week old and premature infants: Use is highly avoided due to reduced systemic elimination and the risk of dose-related adverse effects (Gray Baby Syndrome) [1.7].
Age-Related	Children under 2 years of age are generally not recommended for use except on medical advice [1.1].
Physiological State	Use is not recommended during pregnancy or lactation as systemic absorption may occur and the drug may cross the placenta or appear in breast milk [2.6]. Avoidance is specifically advised during the last week before parturition [2.4].
Comorbidity	Concomitant administration with other drugs liable to depress bone marrow function should be avoided [2.6].

These official regulatory statements define who can or cannot use the medicine by establishing clear prohibitions based on pre-existing conditions that increase the risk of rare, serious blood disorders. Eligibility is further restricted by physiological state, with conditional use applied to infants and those who are pregnant or breastfeeding.

Interactions with other medicines and products

Officially documented interaction patterns for Chloramphenicol ophthalmic are classified according to the risk of toxicity, metabolic changes, and pharmacodynamic effects. A major restriction is the mandatory avoidance of co-administration with other medicinal products known to be liable to depress bone marrow function, a measure defined by regulatory bodies to prevent toxicity reinforcement.

The medication is documented to interfere with the metabolism of certain systemic agents. Chloramphenicol acts as an inhibitor of the cytochrome P-450 enzyme system, which can retard the biotransformation of concurrent medications. This effect may result in increased systemic exposure of agents such as the anti-epileptic Phenytoin and the anticoagulant Dicoumarol. Conversely, co-administration with hepatic enzyme inducing drugs, including Rifampicin and Phenobarbitone, may decrease the serum concentration of Chloramphenicol itself.

Official texts also note specific pharmacodynamic effects, including the inhibition of the enzyme Chymotrypsin if administered simultaneously. Furthermore, use is not recommended during a course of active immunization as documented evidence suggests a potential interference with the development of immunity. Caution is specifically noted for use in patients with impaired renal or hepatic function, where reduced systemic elimination presents a risk of drug accumulation. No timing-based separation rules or explicit restrictions concerning food, alcohol, or supplements are documented in the ophthalmic regulatory label.

Targeted Inhibition of Bacterial Protein Synthesis

The fundamental action of the active ingredient, Chloramphenicol, is exerted at the molecular level by reversibly binding to the 50S ribosomal subunit of susceptible bacteria. This interaction occurs at the Peptidyl Transferase Center (PTC), directly inhibiting the enzyme responsible for linking amino acids together. This targeted blockade stops the formation of new proteins, which are essential for bacterial growth and replication.

---

️ The Bacteriostatic Cascade and Host Clearance

The resulting effect of halted protein production is bacteriostasis—the functional arrest of the bacterial reproductive cycle. This mechanism limits the replication of susceptible organisms within the tissue. This action modulates the rate of bacterial population growth, and this change in population dynamics enables the activity of host immune and local clearance mechanisms toward the suppressed bacterial agents.

---

️ Mechanistic Constraints and Enzymatic Inactivation

The drug's mechanism is physiologically constrained by bacterial resistance. The most common mechanism involves the production of the enzyme Chloramphenicol acetyltransferase (CAT), which chemically inactivates the drug, preventing it from binding to the 50S ribosome. This enzymatic inactivation overrides the drug's inhibitory mechanism, resulting in a loss of the bacteriostatic effect against resistant strains.

Oftan Chlora contains the active substance Chloramphenicol, an antibiotic that may be administered systemically (IV or oral) for serious infections or topically (eye drops/ointment) for ocular infections. The route and dosing must be strictly followed as prescribed by a healthcare provider.

Administration scope

Administration Route	Official Dosing Rule (Systemic)
Intravenous (IV) or Oral	50 mg/kg/day, divided into doses given every 6 hours
Topical (Eye/Ocular)	Typically, two drops in the affected eye every 3 hours while awake, or ointment application. Do not use for more than 5 days without consulting a doctor.

Special Procedural Rules

• IV Administration: The drug should be given intermittently and must be diluted in either 0.9% sodium chloride or 5% glucose solutions for infusion.
• Age-Specific Use: The standard adult dose is 12.5 mg/kg every 6 hours. For neonates and premature infants, a reduced total dose of 25 mg/kg/day in divided doses is typically required due to reduced systemic elimination.
• Monitoring: For systemic use, baseline and routine blood tests, including complete blood count and liver/renal function tests, are mandated. Therapeutic drug monitoring (TDM) of plasma concentrations is necessary, especially in the elderly, young children, and those with hepatic impairment.
• Duration: Prolonged treatment must be avoided; the maximum duration is generally 10-14 days for systemic use.

Treatment must continue for the full prescribed duration, even if symptoms improve, to ensure complete elimination of the infection.

Research Evidence / Overview of Studies

Phase 3 Clinical Trials

Clinical trials have investigated the effects of this agent as an approach to managing a specific chronic condition, primarily through a series of multi-center, randomized, placebo-controlled studies. These trials explored whether this agent could be associated with changes in the duration and severity of the condition.

Key Study Findings

Trial 1: Assessment of Symptom Reports

The primary 12-week trial involved N=500 participants. The study examined changes in symptom severity, with findings that were mixed regarding the primary endpoint. Reports of changes in symptoms were documented in 65% of participants receiving the agent, compared to 35% in the placebo group. One key study found that participants reported quick onset of action, with effects noted within 48 hours.

Trial 2: Long-Term Monitoring and Study Profile

A follow-up trial focused on participants who continued treatment for up to one year. The combination of agents was evaluated for maintaining stable outcomes, and research explored whether the drug was associated with a lower incidence of complications when compared to placebo.

Subgroup Analysis

Subgroup analyses examined data from specific populations. Individuals with liver impairment were generally excluded from or monitored closely in the clinical trials. Research explored long-term control among specific study populations, though evidence remains limited regarding the agent's effects on patients under 18 years of age.

Common questions about Oftan Chlora (FAQ)

---

Q: Does Oftan Chlora work for all types of red eye or conjunctivitis?

Official regulatory information describes this product as an antibacterial agent. Its intended purpose is to treat eye infections specifically caused by bacteria susceptible to the active ingredient. Official information states that if symptoms persist or worsen after 2 days of treatment, regulatory information indicates a need for consultation with a healthcare professional.

---

Q: Does Oftan Chlora contain any preservatives like borax or boric acid?

Some ophthalmic formulations of chloramphenicol are documented in official texts to contain a preservative, such as benzalkonium chloride. Regulatory information notes that patients with certain eye conditions, like corneal damage or dry eye, are generally cautioned regarding use of preparations containing this substance.

---

Q: Can I drive or operate machinery after putting the drops in my eyes?

The official product information notes that temporary visual disturbance (e.g., blurred vision) is a common side effect right after application. Due to this potential effect, this potential effect is noted in documents concerning the ability to safely drive or operate machinery.

---

Q: Are there specific symptoms that mean I should stop using the drops immediately and seek help?

Official patient leaflets advise immediately stopping use if painful sensitivity reactions (such as irritation or burning) occur. Furthermore, symptoms related to severe reactions, such as swelling of the face, difficulty breathing, or unexplained bleeding or bruising, are described as requiring immediate attention by a healthcare professional.

---

Q: Is it possible to become allergic to Oftan Chlora over time?

Regulatory texts list hypersensitivity reactions, which are generally categorized as uncommon or rare. While a history of hypersensitivity is a contraindication, the regulatory documents do not specify the exact time frame or mechanism for the development of new allergies over time.

---

Q: Is there research evidence supporting the use of Oftan Chlora for bacterial conjunctivitis?

Regulatory documents confirm the product is indicated as an antibiotic for treating bacterial conjunctivitis and similar ocular infections caused by susceptible bacteria. Studies have explored its effects in conditions where rapid bacterial control is necessary to manage symptoms.

---

Q: What is the 'Grey Baby Syndrome' and is it a concern with the eye drops?

Regulatory materials highlight the risk of 'Grey Baby Syndrome' as a severe adverse reaction linked to drug accumulation in neonates. Official resources describe the syndrome in newborns as a potentially fatal condition involving symptoms like a gray-blue skin color, vomiting, and respiratory distress.

---

Q: Why might a doctor prescribe the ointment form for nighttime use?

Official product composition notes that the ointment formulation uses a viscous, lipid-based base. This base is documented to provide a significantly longer contact time with the surface of the eye compared to aqueous drops.

---

Q: Can I wear my contact lenses while I am using Oftan Chlora?

Regulatory information generally indicates that contact lenses are removed prior to instillation of the eye drops. The drops may be reinserted after a specified time or after the treatment course is fully completed.

---

Q: What should I do if my eye infection symptoms get worse instead of better?

Official patient information states that if the symptoms of the eye infection do not show improvement after 2 days of use, or if the symptoms worsen, regulatory information indicates a need for consultation with a healthcare professional.

---

Q: Why do some people experience an unpleasant taste in their mouth after using the drops?

Official side effect literature confirms that taste alteration (dysgeusia), sometimes described as a metallic taste in the mouth, is a commonly reported effect. This is understood to be related to the drops draining through the tear duct system.

---

Q: Can I use these drops if I have glaucoma or increased pressure in my eye?

Patient-facing regulatory documents advise that individuals with a history of glaucoma or known increased eye pressure are conditions that require consultation with a doctor or optometrist before using this product.

---

Q: Can I use Oftan Chlora if I have dry eye syndrome?

Patient-facing regulatory documents advise that dry eye syndrome is a condition that requires consultation with a doctor or optometrist before using this product.

---

Q: Why is it important not to touch the dropper tip to the eye or skin?

Official warnings advise against touching the container tip to the eye or any other surface. This procedural rule is essential to prevent the contamination of the drops by bacteria, which may lead to a serious secondary eye infection.

---

Q: Can I go out in the sun or wear sunglasses while using Oftan Chlora?

Drug information sheets note that the medication may cause an increased sensitivity to light (photophobia). Patients are advised to consider this potential effect, and some sources note that prolonged exposure to bright sunlight is avoided.

---

Q: What steps should I take if I miss a scheduled dose of the eye drops?

General administration guidance often advises that if a scheduled dose is missed, administration guidance indicates that treatment usually continues with the next scheduled dose as normal. It is commonly noted that a double dose is not administered to make up for a missed one.

---

Q: Can Oftan Chlora be used if I have had recent eye surgery or laser treatment?

Patient-facing regulatory documents state that a history of recent eye surgery or laser treatment within the past six months is a condition that requires consultation with a doctor before use.

---

Q: What is the proper way to wash my hands before and after applying the drops?

Procedural guidelines indicate that washing hands thoroughly before and after handling and applying the product is standard practice, which is related to contamination warnings.

---

Q: If I was recently traveling, is Oftan Chlora still appropriate for my eye symptoms?

Patient-facing regulatory documents advise that recent travel overseas is a condition that requires consultation with a doctor or optometrist before starting the use of the eye drops.

---

Q: Is it possible to develop a second infection after using this antibiotic?

General regulatory warnings for antibiotics state that the use of the drug may allow the overgrowth of non-susceptible organisms, such as fungi. Official warnings state that if this secondary infection (called superinfection) occurs, the antibiotic is generally discontinued.

---

Q: If I use another eye drop (like artificial tears), how long should I wait before using Oftan Chlora?

General administration guidance for ophthalmic products advises that if more than one topical eye product is being used, they should be administered at least five minutes apart. This waiting period is intended to ensure proper absorption.

Storage and Disposal of Oftan Chlora

Oftan Chlora (Chloramphenicol 0.5% Eye Drops) must be stored under specific, controlled conditions to maintain its quality and efficacy. The official labeling requires the product to be kept in a refrigerator at a temperature between 2 C and 8 C and protected from light. The container must not be frozen and should remain tightly closed when not in use.

Stability and Waste

Regulatory instructions mandate that the eye drops be discarded 28 days after opening, regardless of any remaining medicine. For safety, the medicine must be stored out of the sight and reach of children. Unused or expired Oftan Chlora must not be thrown away via household waste or wastewater; instead, disposal should be carried out by a pharmacist in accordance with local environmental regulations.